Advertisement

Does the ATA Risk Stratification Apply to Patients with Papillary Thyroid Microcarcinoma?

  • Dessislava I. Stefanova
  • Arpita Bose
  • Timothy M. Ullmann
  • Jessica N. Limberg
  • Brendan M. Finnerty
  • Rasa Zarnegar
  • Thomas J. FaheyIII
  • Toni BeninatoEmail author
Original Scientific Report

Abstract

Background

The incidence of papillary thyroid microcarcinoma (PTMC) has increased over the past decade. The American Thyroid Association (ATA) suggests that these patients may undergo either thyroid lobectomy or active surveillance. It remains unclear whether there exists a subgroup of PTMC patients who may benefit from more aggressive treatment due to increased risk of recurrence.

Methods

We retrospectively reviewed 357 patients with PTMC who underwent surgery at a single institution from 2004 to 2016. Patients were classified according to 2015 ATA risk stratification for structural disease recurrence. Demographic, oncologic, and clinicopathologic data were compared between groups.

Results

Out of 357 patients, 246 were classified as low-risk PTMC, 93 were intermediate-risk, and 18 were high-risk. There were more male patients in the high-risk group (38.9%) than the intermediate- (31.2%) or low-risk groups (15.4%) (p < 0.001). Patients with low-risk microcarcinomas were more likely to have an incidental PTMC when compared to intermediate- or high-risk groups (98[39.8%], 15[16.1%], 1[5.6%], respectively, p < 0.001). Patients with high-risk PTMCs, compared to those with intermediate- and low-risk PTMCs, were more likely to have rising postoperative thyroglobulin levels after total thyroidectomy (6[40.0%], 4[5.1%], 9[5.7%], respectively, p = 0.001) and structural recurrence after lobectomy or total thyroidectomy (3[16.7%], 0[0%], 0[0%], respectively, p < 0.001). The median follow-up time was 17.5 (IQR 3–55) months.

Conclusions

Patients with high-risk PTMC have an increased risk of recurrence when compared to low- and intermediate-risk microcarcinomas, whereas intermediate-risk PTMC may behave similarly to low-risk tumors. ATA risk stratification may inform clinical decision making for patients with PTMC.

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Human and animal rights

The study was approved by the institutional review board at Weill Cornell Medicine.

References

  1. 1.
    Lim H, Devesa SS, Sosa JA et al (2017) Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA 317:1338–1348.  https://doi.org/10.1001/jama.2017.2719 CrossRefPubMedGoogle Scholar
  2. 2.
    Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295:2164–2167.  https://doi.org/10.1001/jama.295.18.2164 CrossRefPubMedGoogle Scholar
  3. 3.
    Vigneri R, Malandrino P, Vigneri P (2015) The changing epidemiology of thyroid cancer: why is incidence increasing? Curr Opin Oncol 27:1–7.  https://doi.org/10.1097/CCO.0000000000000148 CrossRefPubMedGoogle Scholar
  4. 4.
    Leboulleux S, Tuttle RM, Pacini F, Schlumberger M (2016) Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance? Lancet Diabetes Endocrinol 4:933–942.  https://doi.org/10.1016/S2213-8587(16)30180-2 CrossRefPubMedGoogle Scholar
  5. 5.
    Ito Y, Tomoda C, Uruno T et al (2004) Papillary microcarcinoma of the thyroid: how should it be treated? World J Surg 28:1115–1121.  https://doi.org/10.1007/s00268-004-7644-5 CrossRefPubMedGoogle Scholar
  6. 6.
    Ito Y, Uruno T, Nakano K et al (2003) An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13:381–387.  https://doi.org/10.1089/105072503321669875 CrossRefPubMedGoogle Scholar
  7. 7.
    Sorrentino F, Atzeni J, Romano G et al (2010) Differentiated microcarcinoma of the thyroid gland. G Chir 31:277–278PubMedGoogle Scholar
  8. 8.
    Mazzaferri EL (2007) Management of low-risk differentiated thyroid cancer. Endocr Pract 13:498–512.  https://doi.org/10.4158/EP.13.5.498 CrossRefPubMedGoogle Scholar
  9. 9.
    Frangos S, Iakovou IP, Marlowe RJ et al (2015) Difficulties in deciding whether to ablate patients with putatively “low-intermediate-risk” differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study. Eur J Nucl Med Mol Imaging 42:2045–2055.  https://doi.org/10.1007/s00259-015-3124-4 CrossRefPubMedGoogle Scholar
  10. 10.
    Dhir M, McCoy KL, Ohori NP et al (2018) Correct extent of thyroidectomy is poorly predicted preoperatively by the guidelines of the American Thyroid Association for low and intermediate risk thyroid cancers. Surgery 163:81–87.  https://doi.org/10.1016/j.surg.2017.04.029 CrossRefPubMedGoogle Scholar
  11. 11.
    Gao R, Jia X, Liang Y et al (2019) Papillary thyroid micro carcinoma: the incidence of high-risk features and its prognostic implications. Front Endocrinol (Lausanne) 10:74.  https://doi.org/10.3389/fendo.2019.00074 CrossRefGoogle Scholar
  12. 12.
    Yu X-M, Wan Y, Sippel RS, Chen H (2011) Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg 254:653–660.  https://doi.org/10.1097/SLA.0b013e318230036d CrossRefPubMedGoogle Scholar
  13. 13.
    Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133.  https://doi.org/10.1089/thy.2015.0020 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kwon H, Jeon MJ, Kim WG et al (2017) A comparison of lobectomy and total thyroidectomy in patients with papillary thyroid microcarcinoma: a retrospective individual risk factor-matched cohort study. Eur J Endocrinol 176:371–378.  https://doi.org/10.1530/EJE-16-0845 CrossRefPubMedGoogle Scholar
  15. 15.
    Kim TY, Shong YK (2017) Active surveillance of papillary thyroid microcarcinoma: a mini-review from Korea. Endocrinol Metab (Seoul) 32:399–406.  https://doi.org/10.3803/EnM.2017.32.4.399 CrossRefGoogle Scholar
  16. 16.
    Tuttle RM, Tala H, Shah J et al (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341–1349.  https://doi.org/10.1089/thy.2010.0178 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Cho J-K, Kim J-Y, Jeong C-Y et al (2012) Clinical features and prognostic factors in papillary thyroid microcarcinoma depends on age. J Korean Surg Soc 82:281–287.  https://doi.org/10.4174/jkss.2012.82.5.281 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Zheng W, Wang X, Rui Z et al (2019) Clinical features and therapeutic outcomes of patients with papillary thyroid microcarcinomas and larger tumors. Nucl Med Commun 40:477–483.  https://doi.org/10.1097/MNM.0000000000000991 CrossRefPubMedGoogle Scholar
  19. 19.
    Mercante G, Frasoldati A, Pedroni C et al (2009) Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid 19:707–716.  https://doi.org/10.1089/thy.2008.0270 CrossRefPubMedGoogle Scholar
  20. 20.
    Cheng F, Chen Y, Zhu L et al (2019) Risk factors for cervical lymph node metastasis of papillary thyroid microcarcinoma: a single-center retrospective study. Int J Endocrinol 2019:8579828.  https://doi.org/10.1155/2019/8579828 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Jeon MJ, Kim WG, Choi YM et al (2016) Features predictive of distant metastasis in papillary thyroid microcarcinomas. Thyroid 26:161–168.  https://doi.org/10.1089/thy.2015.0375 CrossRefPubMedGoogle Scholar
  22. 22.
    Siddiqui S, White MG, Antic T et al (2016) Clinical and pathologic predictors of lymph node metastasis and recurrence in papillary thyroid microcarcinoma. Thyroid 26:807–815.  https://doi.org/10.1089/thy.2015.0429 CrossRefPubMedGoogle Scholar
  23. 23.
    Sugitani I, Fujimoto Y (1999) Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. Endocr J 46:209–216CrossRefGoogle Scholar
  24. 24.
    Arora N, Turbendian HK, Scognamiglio T, et al. (2008) Extrathyroidal extension is not all equal: Implications of macroscopic versus microscopic extent in papillary thyroid carcinoma. Surgery 144:942–7; discussion 947. doi: 10.1016/j.surg.2008.07.023Google Scholar
  25. 25.
    Kazaure HS, Roman SA, Sosa JA (2012) Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol 19:1874–1880.  https://doi.org/10.1245/s10434-011-2129-x CrossRefGoogle Scholar
  26. 26.
    Kuo EJ, Goffredo P, Sosa JA, Roman SA (2013) Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis. Thyroid 23:1305–1311.  https://doi.org/10.1089/thy.2012.0563 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Brito JP, Ito Y, Miyauchi A, Tuttle RM (2016) A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma. Thyroid 26:144–149.  https://doi.org/10.1089/thy.2015.0178 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Sugitani I, Toda K, Yamada K et al (2010) Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg 34:1222–1231.  https://doi.org/10.1007/s00268-009-0359-x CrossRefPubMedGoogle Scholar
  29. 29.
    Kim HJ, Kim NK, Choi JH et al (2013) Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 78:614–620.  https://doi.org/10.1111/cen.12034 CrossRefGoogle Scholar
  30. 30.
    Hu G, Zhu W, Yang W et al (2016) The effectiveness of radioactive iodine remnant ablation for papillary thyroid microcarcinoma: a systematic review and meta-analysis. World J Surg 40:100–109.  https://doi.org/10.1007/s00268-015-3346-4 CrossRefPubMedGoogle Scholar
  31. 31.
    Durante C, Montesano T, Attard M et al (2012) Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? J Clin Endocrinol Metab 97:2748–2753.  https://doi.org/10.1210/jc.2012-1123 CrossRefPubMedGoogle Scholar
  32. 32.
    Ibrahimpasic T, Nixon IJ, Palmer FL et al (2012) Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer–is there a need for radioactive iodine therapy? Surgery 152:1096–1105.  https://doi.org/10.1016/j.surg.2012.08.034 CrossRefPubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2019

Authors and Affiliations

  • Dessislava I. Stefanova
    • 1
  • Arpita Bose
    • 1
  • Timothy M. Ullmann
    • 1
  • Jessica N. Limberg
    • 1
  • Brendan M. Finnerty
    • 1
  • Rasa Zarnegar
    • 1
  • Thomas J. FaheyIII
    • 1
  • Toni Beninato
    • 1
    Email author
  1. 1.Department of Surgery, Weill Cornell Medical CollegeNew York-Presbyterian HospitalNew YorkUSA

Personalised recommendations